Asamura H, Nishimura KK, Giroux DJ, Chansky K, Hoering A, Rusch V and Rami-Porta R: Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, Participating Institutions. IASLC lung cancer staging project: The new database to inform revisions in the ninth edition of the TNM classification of lung cancer. J Thorac Oncol. 18:564–575. 2023.PubMed/NCBI View Article : Google Scholar

Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, Fong KM, Giuliani M, Huang J, Kernstine KH Sr, et al: The international association for the study of lung cancer lung cancer staging project: Proposals for revision Of the TNM stage groups in the forthcoming (Ninth) edition of the TNM classification for lung cancer. J Thorac Oncol. 19:1007–1027. 2024.

Lu S, Lu C, Xiao Y, Zhu W, He Q, Xie B, Zhou J, Tao Y, Liu S and Xiao D: Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer. J Cancer. 11:1525–1531. 2020.

Imyanitov EN, Iyevleva AG and Levchenko EV: Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit Rev Oncol Hematol. 157(103194)2021.

Shields MD, Chen K, Dutcher G, Patel I and Pellini B: Making the rounds: Exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 23(9006)2022.PubMed/NCBI View Article : Google Scholar

Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, Tang XM, Sun F, Lu HM, Deng J, et al: Liquid biopsy in lung cancer: Significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 21(25)2022.PubMed/NCBI View Article : Google Scholar

Hussain MS, Gupta G, Ghaboura N, Moglad E, Almalki WH, Alzarea SI, Kazmi I, Ali H, MacLoughlin R, Loebenberg R, et al: Exosomal ncRNAs in liquid biopsies for lung cancer. Clin Chim Acta. 565(119983)2024.PubMed/NCBI View Article : Google Scholar

Pezzuto A, Terzo F, Graziani ML, Ricci A, Bruno P and Mariotta S: Lung cancer requires multidisciplinary treatment to improve patient survival: A case report. Oncol Lett. 14:3035–3038. 2017.PubMed/NCBI View Article : Google Scholar

Hardavella G, Chorostowska-Wynimko J and Blum TG: Lung cancer: An update on the multidisciplinary approach from screening to palliative care. Breathe (Sheff). 20(240117)2024.PubMed/NCBI View Article : Google Scholar

McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J and Guerrero T: Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys. 76:816–823. 2010.PubMed/NCBI View Article : Google Scholar

Duan Y, Wang Y, Lu S, Zeng M, Liu L, Dai Q and Yin R: Adverse event profile of albumin-bound paclitaxel: A real-world pharmacovigilance analysis. Front Pharmacol. 15(1448144)2024.PubMed/NCBI View Article : Google Scholar

Minguet J, Smith KH and Bramlage P: Targeted therapies for treatment of non-small cell lung cancer-recent advances and future perspectives. Int J Cancer. 138:2549–2561. 2016.PubMed/NCBI View Article : Google Scholar

Wagner SA, Szczesniak PP, Voigt A, Gräf JF and Beli P: Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma. Proteomics. 21(e2000283)2021.PubMed/NCBI View Article : Google Scholar

Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y and Ouyang L: Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm Sin B. 11:355–372. 2021.PubMed/NCBI View Article : Google Scholar

Schoenfeld AJ and Hellmann MD: Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 37:443–455. 2020.PubMed/NCBI View Article : Google Scholar

Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, Brahmer JR, Johnson DH and Sandler A: Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern cooperative oncology group 4599 study: Results of an exploratory analysis. J Thorac Oncol. 7:1707–1712. 2012.PubMed/NCBI View Article : Google Scholar

Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, et al: BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 33:2197–2204. 2015.PubMed/NCBI View Article : Google Scholar

Chu T, Zhang W, Zhang B, Zhong R, Zhang X, Gu A, Shi C, Wang H, Xiong L, Lu J, et al: Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: A three-armed prospective study. Transl Lung Cancer Res. 11:1394–1404. 2022.PubMed/NCBI View Article : Google Scholar

Camerini A, Del Conte A, Pezzuto A, Scotti V, Facchinetti F, Ciccone LP, Perna M, Sartori G, Puccetti C, Ricci A, et al: Selection criteria and treatment outcome for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial. Cancers (Basel). 14(6074)2022.PubMed/NCBI View Article : Google Scholar

Chan BA and Hughes BG: Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 4:36–54. 2015.PubMed/NCBI View Article : Google Scholar

Marmarelis ME and Langer CJ: Treatment of patients with non-small-cell lung cancer harboring rare oncogenic mutations. Clin Lung Cancer. 21:395–406. 2020.PubMed/NCBI View Article : Google Scholar

Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, et al: Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 391:1486–1498. 2024.PubMed/NCBI View Article : Google Scholar

Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, et al: Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions. N Engl J Med. 389:2039–2051. 2023.PubMed/NCBI View Article : Google Scholar

Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, et al: Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov. 12:1676–1689. 2022.PubMed/NCBI View Article : Google Scholar

Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, et al: Phase II study of crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 36:1405–1411. 2018.PubMed/NCBI View Article : Google Scholar

Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, et al: Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 39:1253–1263. 2021.PubMed/NCBI View Article : Google Scholar

Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, et al: Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 390:118–131. 2024.PubMed/NCBI View Article : Google Scholar

Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Tan DSW, Alonso G, Wolf J, Park K, et al: Selpercatinib in patients With RET fusion-positive non-small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 41:385–394. 2023.PubMed/NCBI View Article : Google Scholar

Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, et al: Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial. Ann Oncol. 33:1168–1178. 2022.PubMed/NCBI View Article : Google Scholar

Li C, Nguyen V, Clark KN, Zahed T, Sharkas S, Filipp FV and Boiko AD: Down-regulation of FZD3 receptor suppresses growth and metastasis of human melanoma independently of canonical WNT signaling. Proc Natl Acad Sci USA. 116:4548–4557. 2019.PubMed/NCBI View Article : Google Scholar

Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, et al: Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-Mutant metastatic non-small-cell lung cancer. J Clin Oncol. 41:3700–3711. 2023.PubMed/NCBI View Article : Google Scholar

Rocco D, Gravara LD, Palazzolo G and Gridelli C: The treatment of a new entity in advanced non-small cell lung cancer: MET exon 14 skipping mutation. Curr Med Chem. 31:3043–3056. 2024.PubMed/NCBI View Article : Google Scholar

Bourhis A, Remoué A and Uguen A: KRAS and BRAF double mutations and functional classes of BRAF mutations in non-small-cell lung cancers. Clin Lung Cancer. 21:e240–e242. 2020.PubMed/NCBI View Article : Google Scholar

Yang G, Xu H, Yang Y, Zhang S, Xu F, Hao X, Li J, Xing P, Hu X, Liu Y, et al: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: A prospective, open-label, single-arm phase 2 study (PATHER2). BMC Med. 20(277)2022.PubMed/NCBI View Article : Google Scholar

Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, et al: Open-label, multicenter, phase II study of RC48-ADC, a HER2-Targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 27:43–51. 2021.PubMed/NCBI View Article : Google Scholar

Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, et al: Long-Term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-Year analysis of CodeBreaK 100. J Clin Oncol. 41:3311–3317. 2023.PubMed/NCBI View Article : Google Scholar

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, et al: Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: A randomised, open-label, phase 3 trial. Lancet. 401:733–746. 2023.PubMed/NCBI View Article : Google Scholar

Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, et al: Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 387:120–131. 2022.PubMed/NCBI View Article : Google Scholar

Lorthiois E, Gerspacher M, Beyer KS, Vaupel A, Leblanc C, Stringer R, Weiss A, Wilcken R, Guthy DA, Lingel A, et al: JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS(G12C) for the treatment of solid tumors. J Med Chem. 65:16173–16203. 2022.PubMed/NCBI View Article : Google Scholar

Shi Z, Weng J, Niu H, Yang H, Liu R, Weng Y, Zhu Q, Zhang Y, Tao L, Wang Z, et al: D-1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity. Cancer Sci. 114:2951–2960. 2023.PubMed/NCBI View Article : Google Scholar

Lassen U, Bokemeyer C, Garcia-Foncillas J, Italiano A, Vassal G, Paracha N, Marian M, Chen Y, Linsell L and Abrams K: prognostic value of neurotrophic tyrosine receptor kinase gene fusions in solid tumors for overall survival: A systematic review and meta-analysis. JCO Precis Oncol. 7(e2200651)2023.PubMed/NCBI View Article : Google Scholar

Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, et al: Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 24:997–1007. 2022.PubMed/NCBI View Article : Google Scholar

Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, et al: Patient-reported outcomes from STARTRK-2: A global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open. 6(100113)2021.PubMed/NCBI View Article : Google Scholar

Xu L, Wang F and Luo F: MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis. Front Oncol. 12(1013299)2022.PubMed/NCBI View Article : Google Scholar

Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M and Büttner R: Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol. 84:184–198. 2022.PubMed/NCBI View Article : Google Scholar

Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, et al: The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature. 600:319–323. 2021.PubMed/NCBI View Article : Google Scholar

Poole A, Karuppiah V, Hartt A, Haidar JN, Moureau S, Dobrzycki T, Hayes C, Rowley C, Dias J, Harper S, et al: Therapeutic high affinity T cell receptor targeting a KRAS(G12D) cancer neoantigen. Nat Commun. 13(5333)2022.PubMed/NCBI View Article : Google Scholar

Zhang H, Zhang Y, Zhu Y, Dong T and Liu Z: Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: Clinical insights and perspectives. Front Oncol. 14(1387345)2024.PubMed/NCBI View Article : Google Scholar

Sini C, Tuzi A, Rossi G, Russo A and Pezzuto A: Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncol. 14:29–40. 2018.PubMed/NCBI View Article : Google Scholar

Wu J and Lin Z: Non-Small cell lung cancer targeted therapy: Drugs and mechanisms of drug resistance. Int J Mol Sci. 23(15056)2022.PubMed/NCBI View Article : Google Scholar

Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol Cancer. 22(40)2023.PubMed/NCBI View Article : Google Scholar

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, et al: Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 34:358–376. 2023.PubMed/NCBI View Article : Google Scholar

Levra MG, Cotté FE, Corre R, Calvet C, Gaudin AF, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assié JB and Chouaïd C: Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer. 140:99–106. 2020.PubMed/NCBI View Article : Google Scholar

Brahmer JR, Lee JS, Ciuleanu TE, Caro RB, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, et al: Five-Year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol. 41:1200–1212. 2023.PubMed/NCBI View Article : Google Scholar

Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, et al: Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50%: Randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 39:2327–2338. 2021.PubMed/NCBI View Article : Google Scholar

Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, et al: Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23:781–792. 2022.PubMed/NCBI View Article : Google Scholar

Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S and Croce M: Therapeutic implications of tumor microenvironment in lung cancer: Focus on immune checkpoint blockade. Front Immunol. 12(799455)2021.PubMed/NCBI View Article : Google Scholar

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, et al: Expression analysis and significance of PD-1, LAG-3, and TIM-3 in Human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. 25:4663–4673. 2019.PubMed/NCBI View Article : Google Scholar

Qu J, Mei Q, Chen L and Zhou J: Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): Current status and future perspectives. Cancer Immunol Immunother. 70:619–631. 2021.PubMed/NCBI View Article : Google Scholar

Pockley AG, Vaupel P and Multhoff G: NK cell-based therapeutics for lung cancer. Expert Opin Biol Ther. 20:23–33. 2020.PubMed/NCBI View Article : Google Scholar

Paijens ST, Vledder A, de Bruyn M and Nijman HW: Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 18:842–859. 2021.PubMed/NCBI View Article : Google Scholar

Sadagopan A, Michelakos T, Boyiadzis G, Ferrone C and Ferrone S: Human leukocyte antigen class I antigen-processing machinery upregulation by anticancer therapies in the era of checkpoint inhibitors: A review. JAMA Oncol. 8:462–473. 2022.PubMed/NCBI View Article : Google Scholar

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, et al: Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 359:582–587. 2018.PubMed/NCBI View Article : Google Scholar

Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst. 106(dju124)2014.PubMed/NCBI View Article : Google Scholar

Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Chao J, et al: Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 28:3489–3498. 2022.PubMed/NCBI View Article : Google Scholar

Marei HE, Hasan A, Pozzoli G and Cenciarelli C: Cancer immunotherapy with immune checkpoint inhibitors (ICIs): Potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 23(64)2023.PubMed/NCBI View Article : Google Scholar

Dotsu Y, Muraoka D, Ogo N, Sonoda Y, Yasui K, Yamaguchi H, Yagita H, Mukae H, Asai A and Ikeda H: Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors. J Immunother Cancer. 10(e003958)2022.PubMed/NCBI View Article : Google Scholar

Hong Y, Robbins Y, Yang X, Mydlarz WK, Sowers A, Mitchell JB, Gulley JL, Schlom J, Gameiro SR, Sievers C and Allen CT: Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. JCI Insight. 7(e157448)2022.PubMed/NCBI View Article : Google Scholar

Liu Y, Feng C, Zhou Y, Shao X and Chen M: Simulating the dynamic intra-tumor heterogeneity and therapeutic responses. Cancers (Basel). 14(1645)2022.PubMed/NCBI View Article : Google Scholar

Sharma P, Hu-Lieskovan S, Wargo JA and Ribas A: Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168:707–723. 2017.PubMed/NCBI View Article : Google Scholar

Zhao C, Zhang R, Yang H, Gao Y, Zou Y and Zhang X: Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation. Biochem Pharmacol. 226(116378)2024.PubMed/NCBI View Article : Google Scholar

Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, et al: Efficacy and safety of trastuzumab deruxtecan in patients With HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II Trial. J Clin Oncol. 42:47–58. 2024.PubMed/NCBI View Article : Google Scholar

Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, et al: First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 41:4678–4687. 2023.PubMed/NCBI View Article : Google Scholar

Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Rodríguez LPA, Pacheco JM, Li BT, Planchard D, Baik C, et al: Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 25:439–454. 2024.PubMed/NCBI View Article : Google Scholar

Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, Pérol M, et al: Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-lung02 Trial. J Clin Oncol. 41:4852–4863. 2023.PubMed/NCBI View Article : Google Scholar

Cheng Y, Wu L, Fang Y, Fan Y, Li X, Zhang M, Yu Y, Yao Y, Xu R, Guo J, et al: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): Primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Res. 84(CT248)2024.

Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, et al: Telisotuzumab vedotin monotherapy in patients with previously treated c-Met Protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol. 42:3000–3011. 2024.PubMed/NCBI View Article : Google Scholar

Yu HA, Goto Y, Hayashi H, Felip E, Yang JCH, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, et al: HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 41:5363–5375. 2023.PubMed/NCBI View Article : Google Scholar

Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, Fang W, Guo Y, Han Y, Yang K, et al: BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 25:901–911. 2024.PubMed/NCBI View Article : Google Scholar

Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, et al: Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 33:843–852.e844. 2018.PubMed/NCBI View Article : Google Scholar

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 378:113–125. 2018.PubMed/NCBI View Article : Google Scholar

Gordon LG, Merollini KMD, Lowe A and Chan RJ: A systematic review of financial toxicity among cancer survivors: We can't pay the co-pay. Patient. 10:295–309. 2017.PubMed/NCBI View Article : Google Scholar

Fukuda A and Okuma Y: From rarity to reality: Osimertinib's promising horizon in treating uncommon EGFR mutations in non-small cell lung cancer. Clin Cancer Res. 30:3128–3136. 2024.PubMed/NCBI View Article : Google Scholar

Bortolot M, Cortiula F, Fasola G, De Ruysscher D, Naidoo J and Hendriks LEL: Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials. Cancer Treat Rev. 129(102797)2024.PubMed/NCBI View Article : Google Scholar

Mittal A, Moore S, Navani V, Jiang DM, Stewart DJ, Liu G and Wheatley-Price P: What is ailing oncology clinical trials? Can we fix them? Curr Oncol. 31:3738–3751. 2024.PubMed/NCBI View Article : Google Scholar

Chua AV Jr, Delmerico J, Sheng H, Huang XW, Liang E, Yan L, Gandhi S, Puzanov I, Jain P, Sakoda LC, et al: Under-Representation and under-reporting of minoritized racial and ethnic groups in clinical trials on immune checkpoint inhibitors. JCO Oncol Pract. 22(OP2400033)2024.PubMed/NCBI View Article : Google Scholar

Waqar SN and Govindan R: Novel therapies in cancer: Trials and tribulations. Clin Cancer Res. 30:3655–3657. 2024.PubMed/NCBI View Article : Google Scholar

Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S and Hirsch FR: New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 404:803–822. 2024.PubMed/NCBI View Article : Google Scholar